Related Experiment Video
Updated: Jan 12, 2026
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Chimeric antigen receptor (CAR) T-cell therapy for glioblastoma (GBM): current clinical insights, challenges, and
Chase M Walton1, Marcus Bell1, Richard O'Neil2
1Neurosurgery, Medical University of South Carolina, Charleston, South Carolina, USA.
Abstract:
Glioblastoma (GBM) remains the most lethal primary brain cancer with a median survival of under 2 years despite current best treatment practices. Early immunotherapies, including checkpoint blockade and vaccines, showed safety and immunogenicity but no survival benefit. Chimeric antigen receptor (CAR) T treatments in GBM trials have yielded feasibility and antitumor signals but still lack long-term control. This review synthesizes recent clinical and mechanistic data to establish priorities for clinical trial design, patient selection, and treatment development aimed at achieving durable responses in GBM.Recent trials highlight two consistent observations regarding the delivery of CAR T treatment. First, that CAR T cells can be effectively delivered peripherally rather than requiring direct intracranial administration. And second, multi-antigen, regionally delivered products can induce measurable intracranial responses. These findings indicate that access across the blood-brain barrier is feasible, but persistent function is limited by tumor antigen heterogeneity and an immunosuppressive, myeloid-dominated microenvironment that accelerates T-cell exhaustion.Emerging development strategies reflect these constraints. Broader antigen recognition is being pursued through bivalent and engager-secreting constructs. Locoregional delivery through cerebrospinal fluid spaces enables repeated exposure at multifocal sites. Resistance modules targeting TGF-β (Transforming Growth Factor-beta) signaling and myeloid suppression are being investigated to prolong persistence. Cerebrospinal fluid pharmacodynamic monitoring, such as measuring cytokines, chemokines, and CAR cell kinetics, may support adaptive dosing and minimize corticosteroid use. Patient selection criteria increasingly favor individuals with confirmed target expression, sufficient intratumoral T-cell infiltration, and minimal steroid exposure.Advances in manufacturing, including point-of-care platforms, allogeneic products, and in vivo CAR engineering, aim to shorten production timelines and improve access. Collectively, regional delivery, multi-antigen recognition, and microenvironment resistance constitute the current framework for translating CAR T therapy in GBM from transient responses toward sustained benefit.
Insights
Chimeric antigen receptor (CAR) T-cell therapy shows promise for glioblastoma (GBM) by enabling peripheral delivery and multi-antigen targeting. Strategies to overcome tumor heterogeneity and immunosuppression are key for durable GBM treatment responses.
Area of Science:
- Neuro-oncology
- Immunotherapy
- Cellular Therapy
Background:
- Glioblastoma (GBM) is a highly lethal brain cancer with poor prognosis despite aggressive treatments.
- Previous immunotherapies and early CAR T-cell trials in GBM demonstrated safety and feasibility but lacked survival benefits.
- CAR T-cell therapy faces challenges including blood-brain barrier penetration, tumor antigen heterogeneity, and an immunosuppressive tumor microenvironment.
Purpose of the Study:
- To review recent clinical and mechanistic data on CAR T-cell therapy for GBM.
- To establish priorities for designing clinical trials, selecting patients, and developing treatments for durable GBM responses.
- To identify strategies for overcoming resistance mechanisms and improving CAR T-cell persistence in the GBM microenvironment.
Main Methods:
- Synthesis of recent clinical trial data and mechanistic studies on CAR T-cell therapy in GBM.
- Analysis of CAR T-cell delivery methods (peripheral vs. intracranial) and product characteristics (multi-antigen, regional delivery).
- Evaluation of emerging strategies targeting tumor heterogeneity, immunosuppression, and T-cell exhaustion.
Main Results:
- Peripheral delivery of CAR T-cells is feasible and can induce intracranial responses when using multi-antigen, regionally delivered products.
- Tumor antigen heterogeneity and the myeloid-dominated, immunosuppressive microenvironment limit CAR T-cell persistence and function.
- Emerging strategies include bivalent/engager constructs for broader antigen recognition, locoregional delivery via CSF, and resistance modules against TGF-β and myeloid suppression.
Conclusions:
- Advancements in CAR T-cell therapy for GBM focus on regional delivery, multi-antigen recognition, and overcoming microenvironment resistance.
- Strategies like CSF pharmacodynamic monitoring and improved patient selection (target expression, T-cell infiltration, minimal steroid use) are crucial.
- Manufacturing advances (point-of-care, allogeneic products, in vivo engineering) aim to enhance accessibility and reduce timelines for sustained GBM treatment benefit.
More Related Videos
11:15Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
